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New epidemiological data suggest that the incidence of inflammatory bowel disease (IBD) is increasing. As a result the burden
of disease accounts for more strains to the health care system. The clinical variability queries whether disease characteristics
are related to clinical outcome. Our aim was to delineate the latest results of incidence trends in pediatric IBD and to compare
the first experiences with Paris Classification. Incidence of pediatric IBD has been increasing in Western Europe and in Eastern
Europe. To better characterize IBD, Paris Classification was introduced and validated recently. Ileocolonic involvement is the most
characteristic disease location in Crohn’s disease (CD) based on applying Paris Classification. The rate of perianal disease and
complicated behaviour in CD was similar. It is of interest that CD patients with colonic involvement were less likely to have
stricturing disease compared with patients with ileal involvement. In addition, pancolitis dominated in ulcerative colitis (UC).
However, most countries lack prospective, nationwide epidemiological studies to estimate incidence trends.This review emphasizes
the importance of nationwide registries that enroll all pediatric IBD cases serving reliable data for “everyday practice.” These first
reports have shown that Paris Classification is a useful tool to determine the pediatric IBD phenotype.
1. Introduction
The inflammatory bowel diseases (IBD), Crohn’s disease
(CD), and ulcerative colitis (UC) are chronic inflammatory
disorders of the gastrointestinal tract of unknown etiology.
It is hypothesized that IBD is due to a dysregulated mucosal
immune response to commensal gut flora in genetically
susceptible individuals. However, causes of the dysregulated
immune response are not delineated. The fluctuating disease
course affects quality of life in IBD patients significantly.
Furthermore, CD and UC account for substantial costs to
the health care system and society [1]. New epidemiological
data suggest that the incidence and prevalence of IBD are
increasing. In addition, medical therapy and disease man-
agement have changed significantly in the last decade. IBD
develops during childhood or adolescence in up to 25% of
IBD patients. According to a recent report from the USA the
total hospital charges for pediatric CD increased significantly
from $81 million in 1997 to $194 million in 2009. Similarly,
total hospital charges for UC rose from $53 million in 1997 to
$143 million in 2009 [2].
The clinical presentation of CD andUC is highly variable,
with significant diversity in phenotypes of the diseases [11].
This diversity in adults is specified by differences in the
location, the natural history, and the outcomes. The clinical
heterogeneity raised the question whether disease charac-
teristics (age, location, and behaviour) had been related to
clinical outcome. As a result Vienna and Montreal Classi-
fications have been processed to classify IBD using clinical
and epidemiological features. Patients are classified based
on phenotypic characteristics (age, location, and behaviour).
Oostenbrug et al. analyzed disease characteristics of 292 adult
CD patients according to Vienna classification.The operation
rate was higher in patients with ileocolonic localization (𝑃 <
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Table 1: Incidence rates of pediatric- and adult-onset Crohn’s disease and ulcerative colitis in different countries (/100,000).
Pediatric
Crohn’s disease Adult Crohn’s disease
Pediatric ulcerative
colitis Adult ulcerative colitis
Hungary
(2007–2009/2002–2006) [3, 4] 4.8 8.9 2.1 11.9
Northern France
(1988–1998/2006-2007) [5, 6] 2.3 6.7 0.8 3.4
Nationwide/Madrid, Spain
(2003–2007/2003–2005) [7, 8] 1.7 7.3 0.88 7.1
Copenhagen County, Denmark
(2002–2004/2003–2005) [9, 10] 3.1 8.6 2.7 13.4
0.05) and stricturing and penetrating disease behaviour (𝑃 <
0.001) [12], confirming that disease and epidemiological
characteristics are associated with outcome in CD.
Previous epidemiological studies reported marked dif-
ferences in pediatric- and adult-onset IBD. Nevertheless,
previous classification systems (e.g., Montreal Classification)
were not designed or validated for pediatric patients. The
Paris Classification is a new evidence-based consensus rec-
ommendation for pediatric modification of the Montreal
criteria [13]. So far, this new classification system has only
been applied in a few population-based studies.
In this report we summarize the latest incidence trends of
pediatric IBD and the first experiences with Paris Classifica-
tion.
2. Incidence of Adult-Onset Inflammatory
Bowel Disease and Geographic Distribution
Crohn et al. published a case series with ileitis terminalis
in 1932 where the “terminal” word, contrary to the popular
belief, indicated not the location (terminal ileum) but the
“deadly, terminal disease” [14]. The increasing incidence of
IBD was observed from the middle of the 20th century.
According to the first epidemiological studies the incidence
of IBD differed greatly in geographical areas. The frequency
of IBD was higher in developed countries than in developing
countries and higher in northern areas than in southern
regions (Table 1) [15, 16].
Of note, according to the recent studies the traditional
geographical distribution of IBD has changed in the last 20
years. In most Western countries the incidence of adult UC
and CD has stabilized, while incidence has been rising in
regions with previously low incidence (Southern and Eastern
Europe and Asia). In the latest systemic review about the
changes in the worldwide incidence of IBD the highest
incidence of adult UC was 24.3/105 person-years in Europe,
19.2/105 inNorthAmerica, and 6.3/105 in Asia and theMiddle
East.The highest incidence of adult CDwas 20.2/105 in North
America, 12.7/105 in Europe, and 5.0/105 in Asia and the
Middle East. Furthermore, a statistically significant increase
in incidence of IBD was observed in 75% of CD studies and
60% of UC studies [17]. Extrapolation of the incidence figures
on the total European population indicates around 78.000
new cases of CD and 178.000 of UC yearly [1].The prevalence
of CDmay be up to 1.6million people withCD and 2.1million
people with UC in Europe if reported prevalence rates are
extrapolated for the total European population.
Some studies suggested that the incidence of IBD
decreases from the north to the south comparing incidence
within some countries and between countries. The incidence
of UC in Copenhagen, Denmark (8.1/105), was four times
higher than in Bologna, Italy (1.9/105) [18]. For CD, the
rate of 4.1/105 in Copenhagen was five times higher than in
Galicia, North-West Spain (0–8/105). To establish the north-
south gradient in Europe a prospective study (EC-IBD) was
conducted in 20 centers that focused on frequency of IBD
across the continent. According to the EC-IBD study rates
of UC in northern centers were 40% higher than those in
the south (11.4/105 versus 8.9/105) [18]. It was concluded that
the excess is less than expected on the basis of previous
studies that may suggest an increase in the incidence of IBD
in Southern Europe whereas those in the north may have
reached a plateau. However, some recent studies still show
significant difference in frequency of IBD within countries
in children and in adults [6, 7, 19, 20]. The etiology of the
north-south gradient is not delineated. The latest hypothesis
suggests that level of vitamin D is lower in populations living
in Northern Europe. Vitamin D is known to be an inducer of
NOD2 function and the lack of vitamin D may result in the
lower activity of NOD2 and this factor may contribute to the
higher incidence of CD in regions with low sunrise exposure
[21, 22].
A few population-based cohort data have been reported
from Eastern Europe showing an increase in previously less
industrialized countries recently [23]. The elevating rates of
IBD in these countries could be due to methodological bias
rising awareness of the disease and improved availability of
diagnostic tools. Consequently, a prospective, population-
based cohort study (EpiCom study) was established to
investigate whether there is an east-west gradient in the
incidence of IBD in Europe. Thirty-one centers participated
across Europe and this cohort of IBD patients covers a
background population of 10.1 million people. The overall
annual incidence rates in all Western European centers were
roughly twice as high as rates in all Eastern European centers
for CD (incidence rate ratio (IRR = 1.9)) and UC (IRR =
2.1). The diagnostic approach for CD and UC seemed similar
in Eastern and Western Europe. It is of interest that the
incidences correlated with the GDP of each country [24].
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The difference in incidence between Eastern and Western
Europe and the rapid increase in incidence rates in Eastern
Europe support the role for environmental factors. In the
past two decades there has been a change in the lifestyle in
Eastern Europe, including the diet (western lifestyle). Due to
westernized diet (“junk food,” food additives) luminal antigen
exposure has been changed in this region. This alteration
may be an important trigger in the pathogenesis of IBD
[23].
Briefly, the incidence of IBD is risingwith time around the
world, indicating its emergence as a global disease [17]. The
heterogeneity of IBD frequency in different regions highlights
the role of environmental factors.
3. Incidence of Pediatric-Onset IBD
The majority of pediatric population-based reports before
1990s showed that the incidence of pediatric IBD is rising and
the frequency of CD is higher than that of UC (Figure 1) [25–
27]. Some studies mainly from Northern Europe described
the dominance of UC [28, 29]. Incidence of pediatric IBD
has been also rising according to the registry of Veszprem
Province (Hungary). In CD, incidence increased from 0 in
1977–1981 to 7.2/105 in 2007–2011. The incidence of pediatric
UC increased from 0.7/105 in 1977–1981 to 5.2/105 in 2007–
2011 [30].
Temporal trends in the incidence of pediatric-onset IBD
were controversial until recently (Figures 1 and 2). A system-
atic review describing the epidemiology of childhood-onset
IBD was conducted to evaluate the alteration in incidence
over the last decades. Articles published during 1950–2009
were searched and analyzed. Statistical trends in incidence of
pediatric IBD were tested in nine publications; seven (77.8%)
reported increased incidence over time. Twenty-five studies
calculated temporal trends in CD incidence, and 15 (60.0%)
described a significant increase. Twenty studies analyzed
temporal trends of incidence in UC. Four (20.0%) of them
reported significant increase; however, 13 reports (65.0%)
showed no significant change. Rising rates of pediatric IBD
were observed in both developed and developing nations [31].
Recently a few new epidemiological pediatric cohort
studies revealed an increasing trend in incidence of pediatric
IBD. Hope et al. investigated the incidence rate of pediatric
IBD between 2000 and 2010 in Ireland. Incidence of IBD
was 2.5/105 in 2000 that elevated to 5.6/105 by 2010. The
mean annual increase in CD incidence was 0.153 (𝑃 =
0.04), and for UC it was 0.175 (𝑃 < 0.01) between 2000
and 2010 [32]. Geographically close to Ireland a Scottish
report found a similar rising trend. A national cohort of
prospectively and retrospectively acquired incident cases of
pediatric IBD diagnosed less than 16 years old in pediatric
services in Scotland was captured for the period 2003–2008.
The incidence of CD was 4.75/105, and incidence rate of UC
was 2.06/105. Significant increase in the incidence of IBD
(from 4.45/105, 𝑃 < 0.0001), CD (from 2.86/105, 𝑃 < 0.0001),
and UC (from 1.59/105, 𝑃 = 0.023) was found compared with
data from 1990 to 1995 [33].
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Figure 1: Incidence trends in pediatric Crohn’s disease from 1990 to
2010 [5, 7, 32, 34–39].
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Figure 2: Incidence trends in pediatric Crohn’s disease from 1990 to
2010 [5, 7, 32, 34–39].
The sex- and age-standardized incidence of pediatric
IBD in Northern Stockholm during 2002–2007 was 12.8/105
for IBD, 9.2/105 for CD, and 2.8/105 for UC. An increasing
incidence rate of UC (58.4%, 𝑃 < 0.01) was observed
during the study period. However, temporal trend for the
incidence of IBD (3.2%, 𝑃 = 0.54) was not remarkable.
Meanwhile, the incidence rate of pediatric IBD in Northern
Stockholm was significantly higher in 2002–2007 than that
published in earlier study covering 1990–2001. The former
sharp increase in incidence of pediatric CD seems to reach
a plateau, although at a higher rate than reported from most
other regions in the world [34]. Another Scandinavian report
found similar trends. In Eastern Denmark the frequencies of
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UC and CD have traditionally been similar [40]. The mean
annual incidence rates in a prospective cohort during 2007–
2009 were 6.4/105 for IBD, 3.2/105 for CD, and 3.1/105 for UC.
Themean incidence rates of IBD over the past 12 years (1998–
2009) in Eastern Denmark increased significantly (trend test,
𝑃 = 0.02).
The latest report from Southern Europe was conducted in
Spain. A retrospective survey of patients diagnosed below 18
years of age in the period 1996–2009was performed. Patients’
data were obtained from the hospitals’ databases. Martin-
de-Carpi et al. described also a rise in IBD from 0.97/105
to 2.8/105 during 1996–2009. Although this increase is more
evident for CD (from 0.53/105 to 1.7/105), UC has also risen
(from 0.39/105 to 0.88/105) [7].
An east-west gradient has been reported in adults, as
previously mentioned. A recent study from Eastern Europe
has been published from the north-eastern part of Slovenia.
The mean annual incidence was 7.6/105 for IBD, 4.6/105 for
CD, and 2.8/105 for UC. The incidence of total IBD, CD, and
UC increased from 5.7/105, 3.9/105, and 1.8/105 in the period
2002–2004, respectively, to 8.9/105, 5.0/105, and 3.4/105 in
the period 2008–2010. Data of our prospective Hungarian
Pediatric IBD Registry (HUPIR) are comparable to the rate
of Slovenia. The mean annual incidence rate of pediatric
IBD was 7.48/105, for CD it was 4.72/105, and for UC it was
2.32/105 during 2007–2009 in Hungary [3]. The incidence
of childhood IBD in Eastern Europe seems to be high and
comparable to that in western countries of Europe.
In conclusion, incidence rate of pediatric IBD has been
increasing in Northern and in Southern Europe as well as in
Eastern Europe.
4. Methodological Problems in Assessing
Incidence of IBD in Different Regions
Incidence rates reported in different studies are not always
directly comparable due to heterogeneity in study design and
diagnostic criteria, and these factors can dramatically affect
the incidence rates. A key issue is that some studies use
hospital records while others use surveys and administrative
data. The age limit is an important inclusion criterion with
great impact on incidence rate. Most data are retrospective,
only a few prospective population-based studies were con-
ducted, especially reports fromAsia or Eastern Europe [4, 41].
Furthermore, the incidence rates are often an extrapolation
from one or more regions of a country; however, some
studies reported regional variation in frequency of IBD using
consistent methodologies, implying that different regions
within a country may have different incidence rates [31]. In
summary,most countries lack accurate estimates of incidence
of pediatric IBD.
5. Reasons for Rising Incidence
The cause of increasing incidence is not established. Rising
incidence seems to be true both in children and adults,
suggesting that the apparent increases in IBD incidence are
genuine [42]. Twin studies have shown 16%–36% concor-
dance rates in monozygotic twins and 4% concordance rates
in dizygotic twins suggesting that genetic risk factors have
some role in the pathogenesis of IBD [31]. As a result, in the
absence of large genetic background shifts, changing rates
of IBD incidence highlight the importance of environmental
factors.
The socioeconomic alteration in previously low-incident
areas “from developing to developed” may be related to this
rising occurrence. The spread of western lifestyle seems to
be related to the elevation in incidence of Eastern European
countries and in Asian countries. In concordance, emigrants
of South Asian origin emigrating to Canada and UK have
been observed to have an increased risk for IBD, confirming
that environmental factors contribute to this higher risk [43].
The “cold chain hypothesis” suggested that refrigeration
may have altered the bacterial content of our diet, resulting
in the increased growth of disease-triggering organisms [44].
The well-known “hygiene hypothesis” suggests that a cleaner
environment, smaller families, and lower exposure to farm
animals have resulted in increased risk of IBD in westernized
nations [45]. Furthermore, perinatal and early life events may
also play a significant role in developing IBD [46].
6. Incidence Rates in Childhood in
Different Age Groups
The rising incidence could be the consequence of the shift
towards onset at a younger age; however this increase is
evident in adult [17] and in pediatric-onset IBD [31] as well
[47]. Incidence rate by age groups in childhood could also
bring up further questions.Only a few studies reported trends
of incidence after stratifying the children. Two studies divided
patients into three age groups (0–5 years, 6–10 years, and
11–15 years). Henderson et al. compared incidence rates of
two periods (1990–1995 and 2003–2008) and found that there
was a significant increase in incidence of patients between
11 and 15 years (from 7.8/105 to 11.8/105, 𝑃 = 0.052) and
patients between 6 and 10 years (from 4.3/105 to 7.4/105,
𝑃 = 0.039). Frequency of IBD also increased in children
younger than 5 years, but this trend was not significant (from
0.9/105 to 1.5/105, 𝑃 = 0.292) [33]. This result is similar to
the report from Texas [35]. Incidence of IBD (compared in
periods of 1990–1996 and 1997–2002) increased significantly
in age groups 10–14 years and 15–17 years. However, in
children between 5 and 9 years the rise was not significant
and incidence was stable in children under five. Findings of
a report from California are comparable; the rising trend
of UC over time was significant for the age group 10 to
14 years (comparing periods of 1996–1999, 2000–2002, and
2003–2006), but the trend in children aged 15 to 17 years
was not significant [36]. Chouraki et al. stratified patients
into two age groups (0–9 years and 10–19 years) and also
reported an obvious increase of IBD in older children and
a slight increase in younger children comparing incidence
rate of IBD in 1988–1990 and in 2006-2007 [6]. In contrast
with these findings, Jakobsen et al. did not observe difference
in incidence rates over a 12-year period (1998–2009) after
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stratifying the patients into three 5-year age groups (0–4
years, 5–9 years, and 10–14 years) [48]. The only report
describing a significantly rising incidence of IBD patients
younger than 5 years came from Ontario, Canada [37].
Summarizing these data, only a few studies investigated
long term changes of incidence in children stratified by age.
According to these data, incidence is clearly increasing in
children older than 10 years. In contrast, this trend is not
obvious in children younger than 5 years, suggesting that this
subgroup of patients is unique. One explanation could be
that IBD in younger children is more likely to be genetically
determined, and environmental factors may contribute to
lesser extent to the pathogenesis of intestinal inflammation.
However, in older children increasing incidence by age
highlights the dominant role of environmental triggers. In
conclusion, these results suggest that the rising incidence
occurs mainly in children older than 10 years which could
indicate the importance of environmental factors.
7. First Experiences with Paris Classification of
Patients with Pediatric-Onset IBD
IBD develops during childhood or adolescence in up to 25%
of patients. Pediatric IBD differs in some clinical charac-
teristics from adult IBD. As previously mentioned, CD is
more frequent in children than UC in contrast to adults. A
male genome-wide association dominance has been observed
in children with CD, while females are more frequently
affected in adulthood. Despite higher familial occurrence
of IBD in children genomewide association studies showed
that multiple genes conferring susceptibility are comparable
[49, 50]. A key feature of pediatric-onset IBD is the potential
impaired growth retardation and delayed puberty. According
to previous studies comparing IBD in children and adults
[48, 51, 52], ileocecal location is more common in adults
than in children, while panenteric disease is characteristic
phenomenon in pediatric-onset CD. It is of interest that there
is an association between pediatric CD patients carrying one
of the three NOD2 mutations and ileocolonic involvement
[53]. However, younger children with CD, similar to older
adults and the elderly, are more likely to have colonic disease
[54, 55]. Furthermore, upper gastrointestinal involvement is
more common in pediatric IBD (16–51%). This wide range
is due to two methodical approaches. On one hand, there
is a difference in routine diagnostic procedure in adults and
children, since workup of pediatric IBD includes gastroscopy,
ileocolonoscopy, and small bowel imaging [56]; meanwhile
adult gastroenterologists perform usually ileocolonoscopy
and radiology. This routine may lead to underestimation of
upper gastrointestinal involvement in adult CD patients. On
the other hand, disease involvement was defined as ulceration
or aphthous ulcers in Vienna Classification. However, in
several pediatric reports, microscopic involvement has been
applied as a diagnostic criterion. There is no consensus at
present about what abnormalities should be regarded as
proof of involvement in upper gastrointestinal biopsies.Thus,
many nonspecific findings on gastroduodenal biopsies may
be interpreted as evidence of disease involvement in this
Table 2: Comparison of Montreal and Paris Classifications for
Crohn’s disease based on Levine et al. [13].
Montreal
Classification Paris Classification
Age at
diagnosis
A1: below 17 years
A2: 17–40 years
A3: above 40 years
A1a: 0–<10years
A1b: 10–<17 years
A2: 17–40 years
A3: >40 years
Location
L1: terminal ileal/
limited cecal
disease
L2: colonic
L3: ileocolonic
L4∗: isolated upper
disease
L1: distal 1/3 ileum
/ limited cecal disease
L2: colonic
L3: ileocolonic
L4a: upper disease
proximal to ligament of
Treitz∗
L4b: upper disease distal to
ligament of Treitz and
proximal to distal 1/3
ileum∗
Behaviour
B1: nonstricturing
nonpenetrating
B2: stricturing
B3: penetrating
p: perianal disease
modifier
B1: nonstricturing
nonpenetrating
B2: stricturing
B3: penetrating
B2B3: both penetrating and
stricturing disease, either at
the same or different times
p: perianal disease modifier
Growth —
G0: no evidence of growth
delay
G1: growth delay
∗In both the Montreal and Paris Classification systems L4 and L4a/L4b may
coexist with L1, L2, and L3, respectively.
region [11]. In UC there is also clear difference in disease
location between children and adults. Pediatric-onset UC
patients aremore likely to have pancolitis (60–70%); however,
20–30% of adults present with proctitis.
Due to weaknesses of Montreal Classification with regard
to pediatric IBD, a modified classification (Paris) has been
devised [13].The new Paris Classification included classifying
age at diagnosis as A1a (0 to <10 years), A1b (10 to <17 years),
A2 (17 to 40 years), andA3 (>40 years), distinguishing disease
above the distal ileum as L4a (proximal to ligament of Treitz)
and L4b (ligament of Treitz to above distal ileum), allowing
both stenosing and penetrating disease to be classified in the
same patient (B2B3), denoting the presence of growth failure
in the patient at any time as G1 versus G0 (never growth
failure), adding E4 to denote extent of ulcerative colitis that
is proximal to the hepatic flexure, and denoting ever severe
ulcerative colitis during disease course by S1 (Tables 2 and 3).
7.1. Newly Diagnosed Pediatric IBD Patients According to Paris
Classification. Recently a few center- and population-based
studies analyzed newly diagnosed pediatric IBD patients
according to Paris Classification: (1) a study of prospectively
collected IBD patients younger than 15 years diagnosed
in Northern Stockholm (2002–2007) [34]; (2) a retrospec-
tive study of IBD patients younger than 16 years from
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Table 3: Comparison of Montreal and Paris Classifications for ulcerative colitis based on Levine et al. [13].
Montreal Classification Paris Classification
Extent
E1: ulcerative proctitis
E2: left-sided UC (distal to splenic flexure)
E3: extensive (proximal to splenic flexure)
E1: ulcerative proctitis
E2: left-sided UC (distal to splenic flexure)
E3: extensive (hepatic flexure distally)
E4: pancolitis (proximal to hepatic flexure)
Severity
S0: clinical remission
S1: mild UC
S2: moderate UC
S3: severe UC
S0: never severe∗
S1: ever severe∗
∗Severe defined by Pediatric Ulcerative Colitis Activity Index (PUCAI).
Table 4: Paris Classification of patients with Crohn’s disease in population-based studies in Europe [3, 32, 34, 57, 58].
North-
Eastern
Slovenia
Northern
Stockholm Eurokids
Hungary
(HUPIR) Ireland
Crohn’s disease (𝑛) 43 96 582 247 31
Age, % (𝑛/𝑛)
A1a 15 — 20% (244/1221) 11% (27/247) 26% (8/31)
A1b — — 80% 78% (197/247) 74% (23/31)
A2 — — 9% (23/247)
Location, % (𝑛/𝑛)
L1∗ 20.9% (9/43) 8% (8/96) 16% 13.4% (33/247) 19% (6/31)
L1 + L4a 2.3% — 3.6% (21)
L1 + L4b 0 — 3.4% (20) 3% (7/247) 13% (4/31)
L1 + L4ab 7% — 1.4% (8)
∗L2 4.6% (2/43) 71% (68/96) 28% (159/582) 27.5% (68/247) 45% (14/31)
L2 + L4a 0 — 4.1% (24/582)
L2 + L4b 0 — 3.8% (22/582) 6.8% (17/247) 3% (1/31)
L2 + L4ab 0 — 1.2% (7/582)
∗L3 74.5% (32/43) 20% (19/96) 53% 58.7% (145/247) 32% (10/31)
L3 + L4a 23.3% — 14.3%
L3 + L4b 11.6% — 6.5% 49 16% (5/31)
L3L4ab 16.3% — 4.3%
L4 (Isolated) 0 0 4% (18/582) 0.4% (1/247) 3% (1/31)
All upper gastrointestinal involvement 0.4% (1/247)
L4a 48.9% (21/43) 17% (16/96)
L4b 34.9% (15/43) 1% (1/96)
Behaviour
B1 86% (56/65) 95% (91/96) 82% (959/1177) 12.1% (216/256) 90% (28/31)
B2 6% (4/65) 5% (5) 12% (144/1177) 2.3% (31/256) 6% (2/31)
B3 8% (5/65) 0 5% (55/1177) 1.2% (6/256) 3% (1/31)
B2B3 — 0 2% (19/1177) 0.6% (3/256) —
Perianal disease — 8% (8/96) 9% (114/1207) 14.5% (37/247) 10% (3/31)
Growth (G1)
G1 6.6% (16/244) 23% (4/31)
∗L1 + L4a, L1 + L4b, and L1 + L4ab patients are included in patients with L1 location.
A1a: 0–<10 years, A1b: 10–<17 years, and A2: 17–<40 years. B1: nonstricturing-nonpenetrating; B2: stricturing; B3: penetrating; B2B3: both penetrating and
stricturing; G1: evidence of growth delay; L1: distal 1/3 ileal disease (limited cecal disease); L2: colonic disease; L3: ileocolonic disease; L4: upper gastrointestinal
tract disease; L4a: esophagogastroduodenal disease proximal to ligament of Treitz; L4b: distal to ligament of Treitz.
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Table 5: Paris Classification of ulcerative colitis patients in population-based studies in Europe [3, 32, 34, 57, 58].
North-Eastern Slovenia Northern Stockholm Eurokids Hungary (HUPIR) Ireland
Ulcerative colitis (𝑛) 39 29 578 121 14
E1 5.2% (2/39) 11% (3/29) 5% (27/578) 5% (6/121) 14% (2/14)
E2 25.6% (10/39) 14% (4/29) 18% (104/578) 24.8% (30/121) 14% (2/14)
E3 7.7% (3/39) 4% (1/29) 9% (50/578) 13.2% (16/121) 7% (1/14)
E4 61.4% (24/39) 75% (21/29) 69% (397/578) 57% (69/121) 65% (9/14)
Severity (S1) — — — 18.6% (13/121) 43% (6/31)
E1: ulcerative proctitis; E2: left-sided ulcerative colitis (distal to splenic flexure); E3: extensive colitis (hepatic flexure distally); E4: pancolitis (proximal to hepatic
flexure); S1: severe at some stage.
Ireland; (3) the Eurokids registry, a prospective, center-
based registry of newly diagnosed pediatric IBD patients
in 44 IBD centers in 18 countries [57]; (4) a retrospective
study on a cohort of newly diagnosed children aged 0–18
years from North-Eastern Slovenia (2002–2010) [58]; (5) our
prospective, nationwide, incident cohort of pediatric IBD
patients younger than 18 years from Hungary [3] (Tables 4
and 5). The main findings were similar to earlier reports and
were comparable to each other: (1) ileocolonic involvement
was the characteristic disease location in CD; (2) pancolitis
dominated inUC; (3) rate of perianal disease and complicated
behaviour was similar.
However, the reports from Northern Stockholm and
Ireland showed a higher rate of pure colonic CD than the
others (71% and 45% versus 27–28%), which is in contrast
with most population-based studies from both Europe and
North America [40, 59, 60]. Among earlier studies two
reports described similar figures of isolated colonic CD
(Scotland 66% [51]) and Sweden 43% [61]). Further studies
are needed to determine if these contrasts point to possible
disease-modifying environmental or other factors. However,
all of these studies applied an age limit of 16 years, whereas
the age limit of studies with lower rate of isolated colonic
involvement included patients younger than 18 years. This
difference in inclusion criteria may contribute to a shift of
proportion of patients with purely colonic CD.
7.2. Follow-Up and Paris Classification. Hope et al. followed
up Irish IBD patients for 2 years and found that the progres-
sion of disease extension in CD during the first 2 years of
disease course was not frequent [32].This result is in contrast
with the disease extension presented by van Limbergen et
al. (39% at 2 years) [51] and by Vernier-Massouille et al.
(31% at median follow-up of 84 months) [60]. Analysis of
the 196 childhood-onset CD patients demonstrated that 53
of 196 (27.0%) had panenteric involvement (L3 + L4) at
diagnosis [51]. During 2 years follow-up, 56 (39.1%) children
had progression in disease extension: changes were mostly
due to extension from localized disease to more extensive
disease involving the lower gastrointestinal tract (41/56,
73.2%). Meanwhile, the proportions of disease location in
UC had not changed significantly [51] at last follow-up. The
conflicting results may be due to methodological differences
(longer recruitment and follow-up period in earlier studies).
However, the location of disease changed over time in other
publications conducted in adults as well [62]. This may
query the relationship of disease course and initial disease
characteristics.
In the report from North-Eastern Slovenia progression
of disease extension was also investigated. At diagnosis,
16.3% had panenteric disease (L3L4ab), while extensive
involvement was observed in 21.6% of patients during the
follow-up period [58]. In UC, proportion of patients with
pancolitis (E4) increased from 61.5% to 76.5%, respectively.
At presentation, only 6% of CD patients had stricturing
and 8% had penetrating phenotype, and these complicated
phenotypes doubled during the follow-up. In agreement with
these figures other studies also observed a similar 2-fold rise
in complicated CD behaviour during the follow-up [32, 51,
60]. In UC, rate of patients with pancolitis (E4) increased
from 61.4% to 76.5%.
7.3. Paris Classification and Clinical Characteristics. Associa-
tion of epidemiological anddisease characteristics, like family
history and extraintestinal manifestations (EIM), with phe-
notype according to Paris Classification has been analyzed
in two recent studies. In our study we did not find any
significant relationship between age and gender distribution
or family history, EIM, and disease location in CD or in UC
[3]. In contrast, de Bie et al. described that isolated colonic
disease was recorded in 41% (47/114) of children diagnosed
before 10 years of age compared with 24% (111/467) of older
children (𝑃 < 0.001) [57]. A similar trend was found in
the Hungarian cohort, though the difference was not signif-
icant. The two studies concurred that upper gastrointestinal
involvement was not related to age, gender, family history of
IBD, or presence of EIM. However, Lazarev et al. described
a significantly greater risk for multiple abdominal surgeries
in patients with jejunal involvement than in patients with
upper gastrointestinal involvement proximal to the ligament
of Treitz [63].
According to Eurokids, rate of perianal disease occurred
more often in patients with B3 than in patients with B1
(38% versus 8%, 𝑃 < 0.001) and B2 (38% versus 7%,
𝑃 < 0.001). In addition, patients with L2 disease were less
likely to have stricturing disease complications compared
with patients with L1 or L3 disease (6% versus 21% versus
15%, 𝑃 = 0.005).These latter results were not observed in our
study, which is may be due to the lower number of included
patients (582 versus 247).This discrepancy is probably due to
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the different population of the two studies. Eurokids registry
is not a population-based cohort, but a selection of centers
with special interest in IBD; meanwhile the HUPIR is a
population-based incident cohort involving less severe cases.
This phenomenon emphasizes the importance of nationwide
registries that enroll all pediatric patients with IBD including
less severe cases also.
In conclusion, the first reports have shown that Paris
Classification is a useful tool to determine the characteristic
pediatric CD phenotype. Location of disease is comparable in
studies with Paris Classification to studies classifying patients
according to earlier classification systems.
8. Conclusions
The worldwide increasing trends of IBD incidence seem to
be evident in adults [17] as well as in children [31]. Exploring
increase in incidence of IBDmay provide useful insights into
the pathogenesis, especiallywith regard to environmental fac-
tors related to industrialization, such as changes in hygiene,
a more westernized diet, economic growth, and the shift
from rural to urban environments [42]. Furthermore, clinical
classification, like Paris Classification, may contribute to
define distinct subgroup of patients with different prognosis
with different therapeutical approach.
However, there are several methodological clues that
complicate comparing studies from different regions. Con-
sequently, more prospective, population-based studies (data
should not only come from center specialized for IBD)
are needed to delineate the frequency of IBD and disease
phenotype.
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